ECTRIMS 2022 | Differential diagnosis of MS patients using serum proteomics: disease state & MS subtype

Ferhan Qureshi, BS, Vice President, Octave Bioscience, Menlo Park, CA, describes the results of a study evaluating the performance of the multivariate proteomic multiple sclerosis disease activity (MSDA) test to classify patients from different disease states (multiple sclerosis (MS), healthy controls, inflammatory disease controls, and non-MS neurodegenerative disease controls) and to classify the MS cohort based on their disease subtype (CIS, RRMS, SPMS, and PPMS). The analyses found a promising signal from the proteomic biomarkers identified for disease activity, also to classify patients based on their disease state or MS subtype. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.